OLMA

Latest SEC Filings & News for OLMA

2 most recent filings and news items mentioning OLMA. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day

curl "https://api.brieftape.com/v1/tickers/OLMA/news?limit=20"

Pull OLMA filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

OtherMay 26, 2026Positive

Olema partners with Bayer to study OP-3136 with darolutamide in prostate cancer

Olema Pharmaceuticals announced a clinical trial collaboration with Bayer to evaluate its KAT6 inhibitor OP-3136 in combination with Bayer's darolutamide in metastatic castration-resistant prostate cancer patients, with the Phase 1b/2 study expected to initiate in H2 2026. The pa

View filing at SEC.gov →

RegulatoryMay 21, 2026Positive

Olema's OP-3136 KAT6 inhibitor shows promising Phase 1 data with good tolerability.

Olema Pharmaceuticals announced encouraging initial clinical data from Phase 1 testing of OP-3136, a KAT6 inhibitor, showing no dose-limiting toxicities and tumor shrinkage in two-thirds of patients. The positive safety and efficacy findings support continued development as monot

View filing at SEC.gov →

AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.